Shanghai-based Zai Lab Ltd. acquired the rights to develop and commercialize Regeneron Pharmaceuticals Inc.'s cancer drug REGN1979 in Greater China.
REGN1979 is a bispecific antibody that is being tested in patients with B cell non-Hodgkin lymphoma, the most common type of blood cancer.
Zai Lab is making an up-front payment of $30 million for the rights, and agreed to pay up to a further $160 million if the medicine meets certain milestones. Zai Lab will also contribute to the global development costs of some REGN1979 trials.
New York-based Regeneron will manufacture and supply the drug for development and commercialization in the regions covered: China, Hong Kong, Taiwan and Macau.
The experimental drug holds the orphan drug designation in the U.S. Food and Drug Administration to treat follicular lymphoma and diffuse large B-cell lymphoma, the companies said in a press release.